Biora Therapeutics, Inc.
BIORQ
$0.1174
-$0.0086-6.83%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 86.83% | -31.61% | -128.40% | -184.88% | -4.36% |
| Total Depreciation and Amortization | -45.30% | -49.48% | -45.90% | -51.71% | -46.88% |
| Total Amortization of Deferred Charges | 115.41% | 78.68% | 85.59% | -20.65% | 5.36% |
| Total Other Non-Cash Items | -151.78% | 506.96% | 388.08% | 363.07% | 11.37% |
| Change in Net Operating Assets | 6.09% | -38.20% | 113.54% | 302.49% | 134.59% |
| Cash from Operations | 29.70% | 22.59% | 33.12% | 46.05% | 51.02% |
| Capital Expenditure | -96.33% | 27.94% | 92.27% | 95.33% | 84.86% |
| Sale of Property, Plant, and Equipment | 81.82% | 81.82% | 110.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2,963.27% | 1,181.99% | 754.61% | 96.72% | 80.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -58.65% | -63.28% | -83.77% | 43.37% | -79.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.62% | -121.41% | 292.47% | 310.82% | 221.67% |
| Cash from Financing | -18.81% | -65.32% | -39.17% | 131.06% | -71.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.94% | -7.78% | 39.40% | 69.06% | -38.90% |
